Assessment and optimization of respiratory syncytial virus prophylaxis in Connecticut, 1996–2013

Abstract Respiratory syncytial virus (RSV) causes seasonal respiratory infection, with hospitalization rates of up to 50% in high-risk infants. Palivizumab provides safe and effective, yet costly, immunoprophylaxis. The American Academy of Pediatrics (AAP) recommends palivizumab only for high-risk i...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ben Artin, Virginia E. Pitzer, Daniel M. Weinberger
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/edd104bdfe574c46a8d3b459a2cef3c1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:edd104bdfe574c46a8d3b459a2cef3c1
record_format	dspace
spelling	oai:doaj.org-article:edd104bdfe574c46a8d3b459a2cef3c12021-12-02T16:51:09ZAssessment and optimization of respiratory syncytial virus prophylaxis in Connecticut, 1996–201310.1038/s41598-021-90107-82045-2322https://doaj.org/article/edd104bdfe574c46a8d3b459a2cef3c12021-05-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-90107-8https://doaj.org/toc/2045-2322Abstract Respiratory syncytial virus (RSV) causes seasonal respiratory infection, with hospitalization rates of up to 50% in high-risk infants. Palivizumab provides safe and effective, yet costly, immunoprophylaxis. The American Academy of Pediatrics (AAP) recommends palivizumab only for high-risk infants and only during the RSV season. Outside of Florida, the current guidelines do not recommend regional adjustments to the timing of the immunoprophylaxis regimen. Our hypothesis is that adjusting the RSV prophylaxis regimen in Connecticut based on spatial variation in the timing of RSV incidence can reduce the disease burden compared to the current AAP-recommended prophylaxis regimen. We obtained weekly RSV-associated hospital admissions by ZIP-code in Connecticut between July 1996 and June 2013. We estimated the fraction of all Connecticut RSV cases occurring during the period of protection offered by immunoprophylaxis (“preventable fraction”) under the AAP guidelines. We then used the same model to estimate protection conferred by immunoprophylaxis regimens with alternate start dates, but unchanged duration. The fraction of RSV hospitalizations preventable by the AAP guidelines varies by county because of variations in epidemic timing. Prophylaxis regimens adjusted for state- or county-level variation in the timing of RSV seasons are superior to the AAP-recommended regimen. The best alternative strategy yielded a preventable fraction of 95.1% (95% CI 94.7–95.4%), compared to 94.1% (95% CI 93.7–94.5%) for the AAP recommendation. In Connecticut, county-level recommendations would provide only a minimal additional benefit while adding complexity. Initiating RSV prophylaxis based on state-level data may improve protection compared with the AAP recommendations.Ben ArtinVirginia E. PitzerDaniel M. WeinbergerNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-7 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Ben Artin Virginia E. Pitzer Daniel M. Weinberger Assessment and optimization of respiratory syncytial virus prophylaxis in Connecticut, 1996–2013
description	Abstract Respiratory syncytial virus (RSV) causes seasonal respiratory infection, with hospitalization rates of up to 50% in high-risk infants. Palivizumab provides safe and effective, yet costly, immunoprophylaxis. The American Academy of Pediatrics (AAP) recommends palivizumab only for high-risk infants and only during the RSV season. Outside of Florida, the current guidelines do not recommend regional adjustments to the timing of the immunoprophylaxis regimen. Our hypothesis is that adjusting the RSV prophylaxis regimen in Connecticut based on spatial variation in the timing of RSV incidence can reduce the disease burden compared to the current AAP-recommended prophylaxis regimen. We obtained weekly RSV-associated hospital admissions by ZIP-code in Connecticut between July 1996 and June 2013. We estimated the fraction of all Connecticut RSV cases occurring during the period of protection offered by immunoprophylaxis (“preventable fraction”) under the AAP guidelines. We then used the same model to estimate protection conferred by immunoprophylaxis regimens with alternate start dates, but unchanged duration. The fraction of RSV hospitalizations preventable by the AAP guidelines varies by county because of variations in epidemic timing. Prophylaxis regimens adjusted for state- or county-level variation in the timing of RSV seasons are superior to the AAP-recommended regimen. The best alternative strategy yielded a preventable fraction of 95.1% (95% CI 94.7–95.4%), compared to 94.1% (95% CI 93.7–94.5%) for the AAP recommendation. In Connecticut, county-level recommendations would provide only a minimal additional benefit while adding complexity. Initiating RSV prophylaxis based on state-level data may improve protection compared with the AAP recommendations.
format	article
author	Ben Artin Virginia E. Pitzer Daniel M. Weinberger
author_facet	Ben Artin Virginia E. Pitzer Daniel M. Weinberger
author_sort	Ben Artin
title	Assessment and optimization of respiratory syncytial virus prophylaxis in Connecticut, 1996–2013
title_short	Assessment and optimization of respiratory syncytial virus prophylaxis in Connecticut, 1996–2013
title_full	Assessment and optimization of respiratory syncytial virus prophylaxis in Connecticut, 1996–2013
title_fullStr	Assessment and optimization of respiratory syncytial virus prophylaxis in Connecticut, 1996–2013
title_full_unstemmed	Assessment and optimization of respiratory syncytial virus prophylaxis in Connecticut, 1996–2013
title_sort	assessment and optimization of respiratory syncytial virus prophylaxis in connecticut, 1996–2013
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/edd104bdfe574c46a8d3b459a2cef3c1
work_keys_str_mv	AT benartin assessmentandoptimizationofrespiratorysyncytialvirusprophylaxisinconnecticut19962013 AT virginiaepitzer assessmentandoptimizationofrespiratorysyncytialvirusprophylaxisinconnecticut19962013 AT danielmweinberger assessmentandoptimizationofrespiratorysyncytialvirusprophylaxisinconnecticut19962013
_version_	1718383013823250432

Assessment and optimization of respiratory syncytial virus prophylaxis in Connecticut, 1996–2013

Ejemplares similares